Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ENTONASDAQ:GELSNASDAQ:INDPNASDAQ:SLXN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeENTOEntero Therapeutics$0.42-13.6%$0.52$0.19▼$3.16$1.97M1379,320 shs122,476 shsGELSGelteq$0.98-5.8%$1.79$0.93▼$5.50$9.25MN/A170,513 shs19,233 shsINDPIndaptus Therapeutics$0.52-5.1%$0.81$0.51▼$3.10$7.53M1.6414,435 shs54,153 shsSLXNSilexion Therapeutics$1.05-5.0%$1.22$0.58▼$41.85$8.79M0.1114.06 million shs87,916 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceENTOEntero Therapeutics-0.06%-19.77%-2.95%-22.81%+48,009,900.00%GELSGelteq-0.95%0.00%-36.59%-55.17%+103,999,900.00%INDPIndaptus Therapeutics-6.80%-16.68%-34.46%-34.70%-75.45%SLXNSilexion Therapeutics-5.98%-1.79%+2.80%-45.27%+109,999,900.00%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationENTOEntero Therapeutics0.7306 of 5 stars0.03.00.00.02.60.80.6GELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AINDPIndaptus Therapeutics3.5688 of 5 stars3.55.00.00.03.11.71.3SLXNSilexion TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceENTOEntero Therapeutics 0.00N/AN/AN/AGELSGelteq 0.00N/AN/AN/AINDPIndaptus Therapeutics 3.00Buy$8.501,528.35% UpsideSLXNSilexion Therapeutics 3.00Buy$5.00378.47% UpsideCurrent Analyst Ratings BreakdownLatest ENTO, INDP, SLXN, and GELS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/20/2025SLXNSilexion TherapeuticsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$9.00 ➝ $5.00(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookENTOEntero TherapeuticsN/AN/AN/AN/A$2.31 per shareN/AGELSGelteqN/AN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/A$1.44 per shareN/ASLXNSilexion TherapeuticsN/AN/A$0.72 per share1.46($6.63) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateENTOEntero Therapeutics-$15.80MN/A0.00∞N/AN/A-87.06%-12.01%5/12/2025 (Estimated)GELSGelteqN/AN/A0.00∞N/AN/AN/AN/AN/AINDPIndaptus Therapeutics-$15.42M-$1.62N/AN/AN/AN/A-177.27%-141.06%5/14/2025 (Estimated)SLXNSilexion Therapeutics$260KN/A0.00∞N/AN/AN/A-249.43%5/13/2025 (Estimated)Latest ENTO, INDP, SLXN, and GELS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/4/2025N/AENTOEntero Therapeutics-$0.41N/AN/AN/AN/AN/A3/13/2025Q4 2024INDPIndaptus Therapeutics-$0.41-$0.38+$0.03-$0.38N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthENTOEntero TherapeuticsN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AINDPIndaptus TherapeuticsN/AN/AN/AN/AN/ASLXNSilexion TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioENTOEntero TherapeuticsN/A5.345.34GELSGelteqN/AN/AN/AINDPIndaptus TherapeuticsN/A3.423.42SLXNSilexion TherapeuticsN/A0.850.85Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipENTOEntero Therapeutics12.30%GELSGelteqN/AINDPIndaptus Therapeutics7.06%SLXNSilexion Therapeutics10.95%Insider OwnershipCompanyInsider OwnershipENTOEntero Therapeutics0.49%GELSGelteqN/AINDPIndaptus Therapeutics29.50%SLXNSilexion Therapeutics33.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableENTOEntero Therapeutics94.75 million4.73 millionN/AGELSGelteqN/A9.44 millionN/AN/AINDPIndaptus Therapeutics614.43 million9.96 millionNot OptionableSLXNSilexion TherapeuticsN/A8.42 million1.07 millionN/AENTO, INDP, SLXN, and GELS HeadlinesRecent News About These CompaniesSilexion Therapeutics announces expanded development plan for SIL204March 28, 2025 | markets.businessinsider.comSilexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28, 2025 | globenewswire.comSilexion Therapeutics (NASDAQ:SLXN) Price Target Cut to $5.00 by Analysts at Maxim GroupMarch 23, 2025 | americanbankingnews.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 ConferenceMarch 21, 2025 | quiverquant.comSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer ConferenceMarch 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | finanznachrichten.deSilexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven CancersMarch 18, 2025 | quiverquant.comSilexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 18, 2025 | globenewswire.comSilexion Therapeutics Reports Positive Data From SIL204 In Pancreatic Cancer ModelsMarch 7, 2025 | nasdaq.comSilexion reports initial data from systemic administration of SIL204March 5, 2025 | markets.businessinsider.comSilexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer ModelsMarch 5, 2025 | globenewswire.comPESG Industry Update: Anticipation Rises as Silexion Therapeutics Approaches a Key Preclinical Data That Could Be TransformationalMarch 3, 2025 | tmcnet.comSilexion completes initial study of SIL-204 in pancreatic cancer modelsFebruary 26, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Completion of Initial Study in Orthotopic Pancreatic Cancer Models Evaluating Systemic Administration of SIL-204February 25, 2025 | globenewswire.comGoldman Sachs Group Inc's Strategic Acquisition in Silexion Therapeutics CorpFebruary 10, 2025 | gurufocus.comSilexion Therapeutics Corp’s Stock Drama: Could This Be a Game-Changer for SLXN Investors?February 3, 2025 | bovnews.comSilexion Therapeutics Corp (SLXN) Stock: A Deeper Look at Its True PotentialJanuary 31, 2025 | bovnews.comSilexion Therapeutics (SLXN) Gets a Buy from Maxim GroupJanuary 31, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWarren Buffett Swaps VOO for This Reliable Dividend StockBy Sarah Horvath | March 7, 2025View Warren Buffett Swaps VOO for This Reliable Dividend StockNVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBy Thomas Hughes | March 12, 2025View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a BuyBYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?By Jeffrey Neal Johnson | March 21, 2025View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?3 Defense Stocks Set to Benefit From Increased Military SpendingBy Chris Markoch | March 20, 2025View 3 Defense Stocks Set to Benefit From Increased Military SpendingOccidental Petroleum: 4 Reasons to Love These PricesBy Jea Yu | March 17, 2025View Occidental Petroleum: 4 Reasons to Love These PricesENTO, INDP, SLXN, and GELS Company DescriptionsEntero Therapeutics NASDAQ:ENTO$0.42 -0.07 (-13.56%) As of 02:24 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Entero Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of targeted and orally delivered therapies for the treatment of patients with gastrointestinal diseases. The company's pipeline candidates include latiglutenase, a targeted oral biotherapeutic for celiac disease designed to breakdown gluten into non-immunogenic peptides, currently under Phase 2 studies; and capeserod, a selective 5-HT4 receptor partial agonist under Phase 1 studies for the treatment of gastroparesis. It is also involved in the development of adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients, currently under Phase 2 studies for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis; and niclosamide, an oral small molecule with anti-inflammatory inhibitor therapy, currently under Phase 2 studies for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis, as well as immune checkpoint inhibitor-associated colitis and diarrhea in metastatic cancer patients. The company was formerly known as First Wave BioPharma, Inc. and changed its name to Entero Therapeutics, Inc. in May 2024. Entero Therapeutics, Inc. was incorporated in 2014 and is based in Boca Raton, Florida.Gelteq NASDAQ:GELS$0.98 -0.06 (-5.77%) As of 01:44 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.Indaptus Therapeutics NASDAQ:INDP$0.52 -0.03 (-5.07%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.Silexion Therapeutics NASDAQ:SLXN$1.04 -0.06 (-5.00%) As of 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy Amazon Falls Back to a Key Support Line: Here's How to Play It Berkshire Hathaway Gains Defy Stock Market Slump Tech Sell-Off Makes Microsoft Stock Look Like a Steal Palantir Stock Builds Momentum on New Partnership Amprius Market Gets Amped Up on Growth Outlook 3 Buyable Stocks With Solid Bottoms Ready to Rebound Game-Changing News for Advanced Micro Devices Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
